BlossomHill Therapeutics, Inc. 3Q 2026: Net loss $(23.8) M, EPS $(8.75) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.BlossomHill Therapeutics reported a net loss of $23.8M and diluted EPS of $(8.75) for Q3 2026, widening from the prior year's $13.2M loss. The company generated no revenue as it remains clinical-stage. Key developments include enrollment in the SOLARA Phase 1/2 trial for BH-30643, ongoing dose escalation for BH-30236 in AML/MDS, and preclinical work on BH-501284. Cash reserves are expected to fund operations through Q2 2028.
BlossomHill Therapeutics, Inc. reported a net loss of $(23.8) M for the three months ended June 30, 2026, compared with a $(13.2) M loss in the year-ago quarter; diluted loss per share was $(8.75) versus $(5.51) in the prior-year quarter. The company reported no product revenue for the periods presented as it continues to operate as a clinical-stage biopharmaceutical company.
Financial Highlights
- Net income: $(23.8) M net loss for the three months ended June 30, 2026, versus $(13.2) M in the year-ago quarter (≈ $(10.5) M wider YoY).
- Diluted EPS: $(8.75) for the three months ended June 30, 2026, versus $(5.51) in the year-ago quarter.
- Revenue: Not reported for the periods presented (company has no product sales; all periods show net loss).
Business Highlights
- Clinical progress: SOLARA Phase 1/2 is enrolling for BH-30643 with confirmed responses, including in the C797S cohort; chemotherapy combination cohorts are planned.
- Pipeline expansion: BH-30236 Phase 1 dose escalation is ongoing in relapsed/refractory AML and high-risk MDS, with exploration of venetoclax combinations and additional myeloid indications.
- Preclinical advancement: IND-enabling work for BH-501284 is underway with an IND planned in Q1 2027 for a pan‑KRAS candidate.
- Operational build-out: R&D headcount has increased and the company is expanding clinical sites and manufacturing to support multiple clinical programs.
- Liquidity runway & plans: IPO proceeds plus cash are expected to fund operations into Q2 2028, enabling a pivotal Phase 2 start for BH-30643 in 2027.
Original SEC Filing: BlossomHill Therapeutics, Inc. [ BLSM ] - 10-Q - Sep. 18, 2026